Noxopharm aims for autoimmune market with first human trial of SOF-SKN
Noxopharm Ltd is planning the first human trial to assess novel drug SOF-SKN, which aims to treat autoimmune conditions.
TPI
4.29%
73.0¢
TRANSPACIFIC INDUSTRIES GROUP LTD - Announcements
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results